(1.20%) 5 070.55 points
(0.69%) 38 504 points
(1.59%) 15 697 points
(0.07%) $83.42
(-0.33%) $1.806
(-0.08%) $2 340.30
(0.32%) $27.45
(0.26%) $925.20
(-0.03%) $0.934
(-0.13%) $10.89
(-0.02%) $0.803
(-0.10%) $93.10
Live Chart Being Loaded With Signals
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease...
Stats | |
---|---|
Today's Volume | 8.54M |
Average Volume | 4.13M |
Market Cap | 178.08M |
EPS | $0 ( 2024-02-25 ) |
Last Dividend | $1.237 ( 1999-09-24 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.17 |
ATR14 | $0.00200 (0.61%) |
Volume Correlation
Dimerix Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dimerix Ltd Correlation - Currency/Commodity
Dimerix Ltd Financials
Annual | 2023 |
Revenue: | $8.98M |
Gross Profit: | $8.93M (99.38 %) |
EPS: | $-0.0424 |
Q2 | 2023 |
Revenue: | $133 060 |
Gross Profit: | $133 060 (100.00 %) |
EPS: | $-0.0164 |
Q4 | 2023 |
Revenue: | $8.98M |
Gross Profit: | $8.98M (100.00 %) |
EPS: | $-0.0125 |
Q3 | 2022 |
Revenue: | $4.49M |
Gross Profit: | $4.49M (100.00 %) |
EPS: | $-0.00640 |
Financial Reports:
No articles found.
Dimerix Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $6.93 | 1998-09-18 |
Last Dividend | $1.237 | 1999-09-24 |
Next Dividend | $0 | N/A |
Payout Date | 1999-05-21 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $8.16 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.29 | -- |
Div. Sustainability Score | 4.82 | |
Div.Growth Potential Score | 0.335 | |
Div. Directional Score | 2.58 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MVF.AX | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
WAM.AX | Ex Dividend Knight | 2023-10-17 | Semi-Annually | 0 | 0.00% | |
EGG.AX | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
PBH.AX | No Dividend Player | 2023-09-06 | Insufficient data to determine frequency | 0 | 0.00% | |
ALL.AX | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% | |
GOZ.AX | Ex Dividend Junior | 2023-06-29 | Semi-Annually | 0 | 0.00% | |
REH.AX | Ex Dividend Knight | 2023-10-10 | Semi-Annually | 0 | 0.00% | |
BOQ.AX | Ex Dividend Knight | 2023-05-10 | Annually | 0 | 0.00% | |
KPG.AX | Ex Dividend Knight | 2023-07-20 | Monthly | 0 | 0.00% | |
SPK.AX | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.192 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.720 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.83 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.84 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.84 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.76 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0947 | -1.500 | 8.42 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.00174 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.00172 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.832 | -1.500 | 6.67 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.494 | 1.000 | 8.37 | 8.37 | [0.2 - 2] |
assetTurnoverTTM | 0.604 | 0.800 | 9.31 | 7.44 | [0.5 - 2] |
Total Score | 4.82 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -11.01 | 1.000 | -1.214 | 0 | [1 - 100] |
returnOnEquityTTM | -2.83 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.00172 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.00174 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0126 | 1.500 | -3.25 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0774 | 1.000 | -0.566 | 0 | [0.1 - 0.5] |
Total Score | 0.335 |
Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators